First US case of H5N9 bird flu strain found in California
This H5N9 strain, which was identified earlier this month, is different from the H5N1 strain that had already been documented in multiple cases across the U.S. According to the Centers for Disease Control and Prevention, there have been more than 60 people who have been sickened and one person who was killed by H5N1.
2 cats die from suspected bird flu traced to raw milk in California
In a notification, the World Organisation for Animal Health confirmed that the strain detected in Merced County is a new strain in the country. The investigation began on Nov. 23, 2024, and it was confirmed on Jan. 13 that 'this is the first confirmed case of HPAI H5N9 in poultry in the United States.'
The USDA Animal and Plant Health Inspection Service (APHIS), in conjunction with State Animal Health and Wildlife Officials, are conducting comprehensive epidemiological investigations and enhanced surveillance in response to the HPAI related events.
World Organisation for Animal Health
This strain of H5N9 was found in a commercial duck premises in Merced County. The specific location of the facility was not officially released.
The announcement states that control measures have been undertaken in an attempt to contain the virus, including control of movement, surveillance and quarantine. The report from the World Organisation for Animal Health also stated that a total of 118,954 birds were killed in December after state officials quarantined the affected area.
'Bird flu symptoms': Online searches spike after first severe case in US
Bird flu is primarily spread by wild birds such as ducks and geese as they migrate. While it is fatal to a variety of animals, those species can generally carry it without getting sick, which offers the virus a chance to mutate and thrive.
The virus can be spread through droppings or any interaction between farm-raised poultry and wild birds. It's also easily tracked into a farm on someone's boots or by vehicle.
Unlike previous outbreaks, the one that began in 2022 didn't die out in high summer temperatures.
The virus found another new host when dairy cattle started getting sick last March. That creates more opportunities for the virus to linger and spread and unlike poultry, cattle aren't slaughtered when they get sick because they rarely die from bird flu.
Nearly all of the people infected with bird flu worked around sick animals. Health officials haven't yet found evidence of the disease spreading from person to person.
The Associated Press contributed to this report.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
2 days ago
- UPI
Scientists sequence avian flu genome found in Antarctica
Penguins line the shore in South Georgia, Antarctica. A team of Chilean scientists has sequenced the first complete genomes of the H5N1 avian influenza virus found in birds in Antarctica. File Photo by L.A. Kelly Whybrow/Royal Nacy/EPA Aug. 15 (UPI) -- A team of Chilean scientists has sequenced the first complete genomes of the H5N1 avian influenza virus found in birds in Antarctica. The work, led by the University of Chile and the Chilean Antarctic Institute, was published in Emerging Infectious Diseases, a journal of the U.S. Centers for Disease Control and Prevention, marking a milestone in pathogen research on the frozen continent. The study, which included sequencing the virus in birds such as Antarctic skuas and terns, provides crucial information for understanding the evolution of H5N1 and its potential spread to other species. Sequencing a virus's genome is like reading its complete genetic code. In this case, genomic analysis of avian flu found in Antarctica showed the virus is part of the variant that has affected South America. "Sequencing and genetically characterizing this virus in Antarctic birds allows us to understand its behavior in an extreme, pristine and particularly vulnerable ecosystem," said Víctor Neira, a professor at the University of Chile's Faculty of Veterinary and Animal Sciences and a member of the research team. Specifically, the phylogenetic analysis showed a high genetic similarity to viruses detected in gulls and fur seals on South Georgia Island, confirming the existence of a viral migration route from South America to Antarctica. The finding underscores the need for constant global epidemiological surveillance and highlights the virus's risk of mutation, experts said. By infecting new species in a different environment, the virus could become more dangerous and pose a threat to human and animal health worldwide. According to the research team, its greatest contribution to Antarctic science is providing essential data on biodiversity and emerging risks in the region. In late 2023, H5N1 reached Antarctica for the first time, breaking the isolation that had kept the continent free of the virus. The first cases were recorded in skuas on South Georgia Island, and during 2024 and 2025, the virus spread to the Antarctic Peninsula and the Weddell Sea, affecting birds such as penguins, cormorants and gulls, as well as marine mammals including fur seals and elephant seals. Recent scientific expeditions detected nearly 200 infected animals from 13 species in more than 20 locations, confirming the outbreak has taken hold in the region and poses a serious threat to its fragile biodiversity.
Time Magazine
3 days ago
- Time Magazine
Cutting mRNA Research Could Be Our Deadliest Mistake Yet
The U.S. Department of Health and Human Services (HHS) recently announced it will wind down funding for mRNA vaccine development—which could prove to be one of the costliest, deadliest decisions HHS Secretary Robert F. Kennedy Jr. will make during his tenure. HHS has already scaled back access to and recommendations for COVID-19 vaccines—a decision experts are deeply concerned about—and Kennedy's frequently misinformed views on vaccines continue to fan the flames of anti-vaccination attitudes. Now, Kennedy's failure to fully explore the potential of mRNA vaccines could stagnate research that has the potential to save millions of lives around the world. The dark cloud of COVID-19, one of the deadliest infectious disease outbreaks in history, can hardly be thought of as having a silver lining. But the nearest thing to a glimmer of a positive would be that the fast development of COVID-19 vaccines helped prevent many more deaths and led to rapid progress in our understanding and use of mRNA technology. This greater understanding is now being explored as potential preventions or therapies for a wide range of diseases, from H5N1 bird flu and HIV to cancer. Terminating 22 mRNA projects will not only directly set back research on mRNA vaccines for infectious diseases including flu; it will also arguably have negative knock-on effects for researchers the world over exploring personalized treatments for noncommunicable diseases like cancer. Early research on some novel uses of mRNA is promising. For example, a preliminary trial of an mRNA HIV vaccine found that 80% of participants generated neutralizing antibodies, which in theory could help block HIV—pending further research and development. A melanoma mRNA vaccine, when combined with existing treatment, reduced the risk of death or disease recurrence by nearly 50%. (The vaccine is currently being tested further in a full scale Phase 3 clinical trial). Even more amazingly, personalized vaccines—where vaccines are created specifically for an individual using information from their cancer to optimize their immune response—using mRNA technology have even been proposed as a universal vaccine adaptable for all cancers. Read More: The CDC Shooting is a Dark Sign for Science and America Much of the research on personalized mRNA cancer vaccines is in some way indebted to gains in knowledge made from COVID-19 research, and it stands to reason that pulling such a large amount of funding from mRNA projects will slow down further progress in these areas. Approximately $500 million worth of research funding would almost certainly have advanced the scientific community's fundamental understanding of how, and to what extent, mRNA technology works and how it could be applied to prevent and fight disease. Also problematic is the manner in which HHS under Kennedy conveys their decisions. In announcing the funding withdrawal, HHS states it 'will focus on platforms with stronger safety records and transparent clinical and manufacturing data practices.' This implies that mRNA vaccines have not been properly or transparently tested—which is not true. The safety of COVID-19 mRNA vaccines has been demonstrated in numerous studies and systematic evidence reviews. Like pretty much all vaccines and treatments, mRNA vaccines are not without side effects, but evidence shows that any adverse events are nearly always mild and short-lived. COVID-19 vaccines have already saved millions of lives globally, with mRNA vaccines accounting for a significant majority of all doses administered in many countries. Kennedy's claim that 'mRNA technology poses more risk than benefits' is almost farcical in light of scientific evidence. Moreover, the whole purpose of clinical research is to test whether new scientific innovations—like novel applications of mRNA into different diseases—are safe and effective in the first place. Kennedy has long spoken of how we need more evidence and testing on mRNA vaccines, and so it is painfully ironic that he is pulling funding for research which would enable the scientific community to do just that. Read More: An mRNA Melanoma Vaccine Shows Promise Perhaps most concerning is the caliber of evidence upon which decisions with such massive implications are being made. In an HHS announcement of the termination of mRNA projects, Kennedy claims 'the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu.' The truth is, initial vaccines and booster doses have been shown to be very effective against reducing infection, hospitalization, and death from COVID-19. Kennedy does not even provide links or citations to systematic reviews or meta-analyses in reputable journals, the gold standard methods for scientific evidence. Rather, he simply links to an online evidence review which cherry picks studies searching only for the harms—and not the overall safety, effectiveness, or cost-benefit analysis—of the mRNA vaccines. The report does not describe the methods used to select and review studies, nor does it appear itself to have been peer-reviewed by other scientists. It almost certainly wouldn't be publishable in a scientific journal, yet it is being used as evidence to justify the fate of half a billion dollars of research funds. This is another example of how fringe viewpoints on mRNA technology, instead of the best available scientific evidence, are under Kennedy and HHS becoming the new mainstream. The U.S. has been at the forefront of developing mRNA technology for the past few decades, from the Nobel Prize-winning research of professors Katalin Kariko and Drew Weissman at the University of Pennsylvania on mRNA, to the key role of U.S.-based pharmaceutical companies in vaccine production and rollout. Perhaps other countries, companies, and funding sources will offset this funding loss and lead the development of mRNA vaccine innovations. Large investments are already being made in the U.K. and China, for example. That would be to the detriment of U.S. scientific innovation and progress. Kennedy is right to scrutinize the potential overreach of the pharmaceutical industry, and to ensure their research and development is ethical and transparent. However, his seemingly personal war against "Big Pharma" and ideological opposition to mRNA risks stunting research that could one day help prevent the next pandemic or even provide cures for hitherto incurable cancers.
Newsweek
7 days ago
- Newsweek
Trump's Ex-Surgeon General Attacks Vaccine Cuts: 'People Are Going To Die'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump's former Surgeon General Jerome Adams has warned that "people are going to die" if the United States cuts funding for mRNA vaccine development. It comes after Health and Human Services Secretary Robert F. Kennedy Jr. announced last week that his department would terminate 22 Biomedical Advanced Research and Development Authority (BARDA) investments in mRNA vaccine development, representing nearly $500 million in federal funding. He said the decision was taken after reviews showed mRNA vaccines "failed protect effectively against upper respiratory infections like COVID and flu." Newsweek contacted the United States Department of Health and Human Services (HHS) for comment via email outside of regular working hours. Former Surgeon General Jerome Adams speaking at the White House in April 2020. Former Surgeon General Jerome Adams speaking at the White House in April 2020. AP Why It Matters Kennedy has been a longtime vaccine critic, and questioned their effectiveness on numerous occasions. His tenure as the head of HHS has seen top vaccine experts, food safety supervisors and other public-health officials either resign or be ousted. The 22 projects are led by major pharmaceutical companies, including Pfizer and Moderna, and aim to develop vaccines against the flu, COVID-19 and H5N1. mRNA technology, which underpins these vaccines, is widely credited with helping slow the spread of the coronavirus during the 2020 pandemic. Infectious-disease specialists have also warned that future pandemics will be harder to stop without the help of mRNA. What To Know Adams, who served in Trump's first administration, said in an interview with CBS News on Sunday that mRNA technology accelerated vaccine development by an estimated 18 to 24 months. He added that "by the most conservative estimates, at least 2 million lives were saved" during the pandemic because of mRNA vaccines. "It's a natural molecule that's in all of our bodies. It's like a recipe card that tells your body how to make a protein," he said. "And this new idea, again, helps us develop vaccines and new treatments for everything from cancer, melanoma - which my wife has - to HIV, to better flu vaccines." He added: "These are advances that are not going to happen now... people are going to die because we're cutting short funding for this technology." Several other infectious disease experts have also spoken out against Kennedy's decision. Rick Bright, the former director of BARDA, said on X: "A bad day for science, and huge blow to our national security. This decision will have dangerous repercussions." Dr. Thomas A. Russo, an expert in infectious diseases, told Newsweek that Kennedy's decision was "shortsighted," and said mRNA vaccines "will be critical when the next, inevitable infectious diseases crisis rears its ugly head." What People Are Saying RFK Jr. said on X last week: "We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu." Infectious diseases expert Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security, who specializes in pandemic preparedness, told Newsweek: "RFK's actions are completely devoid of value. They are only designed to serve more distrust of a proven and valuable vaccine technology. The repercussions of this decision will serve only to diminish the resiliency of the United States, and the world, to infectious disease threats." What Happens Next In his statement, Kennedy urged the department to shift from mRNA vaccines and "invest in better solutions," but did not specify alternatives. Lawmakers, public-health officials, and industry leaders are expected to press HHS for detailed timelines and alternative research investments options.
